Evaluation of quality of life in breast cancer patients who underwent breast-conserving surgery or mastectomy using real-world data
CONCLUSIONS: At 24 months after MAS, breast cancer patients' QoL improved compared with BCS, although impairments in QoL were reported immediately after MAS. A growing expertise in surgical procedures as well as supportive care is critical to optimizing patients' well-being. These findings may be considered when counseling breast cancer patients pre- and post-surgery.TRIAL REGISTRATION NUMBER: DRKS00013335 on 27/11/2017 retrospectively registered.PMID:37587322 | DOI:10.1007/s12282-023-01494-x (Source: Breast Cancer)
Source: Breast Cancer - August 16, 2023 Category: Cancer & Oncology Authors: Shiao Li Oei Anja Thronicke Gerrit Grieb Friedemann Schad Jessica Gro ß Source Type: research
Evaluation of quality of life in breast cancer patients who underwent breast-conserving surgery or mastectomy using real-world data
CONCLUSIONS: At 24 months after MAS, breast cancer patients' QoL improved compared with BCS, although impairments in QoL were reported immediately after MAS. A growing expertise in surgical procedures as well as supportive care is critical to optimizing patients' well-being. These findings may be considered when counseling breast cancer patients pre- and post-surgery.TRIAL REGISTRATION NUMBER: DRKS00013335 on 27/11/2017 retrospectively registered.PMID:37587322 | DOI:10.1007/s12282-023-01494-x (Source: Breast Cancer)
Source: Breast Cancer - August 16, 2023 Category: Cancer & Oncology Authors: Shiao Li Oei Anja Thronicke Gerrit Grieb Friedemann Schad Jessica Gro ß Source Type: research
MicroRNAs mediated interaction of tumor microenvironment cells with breast cancer cells during bone metastasis
Breast Cancer. 2023 Aug 14. doi: 10.1007/s12282-023-01491-0. Online ahead of print.ABSTRACTBreast cancer (BC) bone metastasis is primarily osteolytic and has limited therapeutic options. Metastasized BC cells prime the secondary environment in bone by forming a tumor niche, which favors their homing and colonization. The tumor microenvironment (TME) is primarily generated by the cancer cells. Bone TME is an intricate network of multiple cells, including altered bone, tumor, stromal, and immune cells. Recent findings highlight the significance of small non-coding microRNAs (miRNAs) in influencing TME during tumor metastasis...
Source: Breast Cancer - August 14, 2023 Category: Cancer & Oncology Authors: R L Akshaya I Saranya N Selvamurugan Source Type: research
Breast cancer screening guidelines: discrepancies raise concerns about validity
Breast Cancer. 2023 Aug 14. doi: 10.1007/s12282-023-01493-y. Online ahead of print.NO ABSTRACTPMID:37578598 | DOI:10.1007/s12282-023-01493-y (Source: Breast Cancer)
Source: Breast Cancer - August 14, 2023 Category: Cancer & Oncology Authors: Nikita Jhangiani Megha Philip Ismail Jatoi Source Type: research
MicroRNAs mediated interaction of tumor microenvironment cells with breast cancer cells during bone metastasis
Breast Cancer. 2023 Aug 14. doi: 10.1007/s12282-023-01491-0. Online ahead of print.ABSTRACTBreast cancer (BC) bone metastasis is primarily osteolytic and has limited therapeutic options. Metastasized BC cells prime the secondary environment in bone by forming a tumor niche, which favors their homing and colonization. The tumor microenvironment (TME) is primarily generated by the cancer cells. Bone TME is an intricate network of multiple cells, including altered bone, tumor, stromal, and immune cells. Recent findings highlight the significance of small non-coding microRNAs (miRNAs) in influencing TME during tumor metastasis...
Source: Breast Cancer - August 14, 2023 Category: Cancer & Oncology Authors: R L Akshaya I Saranya N Selvamurugan Source Type: research
Breast cancer screening guidelines: discrepancies raise concerns about validity
Breast Cancer. 2023 Aug 14. doi: 10.1007/s12282-023-01493-y. Online ahead of print.NO ABSTRACTPMID:37578598 | DOI:10.1007/s12282-023-01493-y (Source: Breast Cancer)
Source: Breast Cancer - August 14, 2023 Category: Cancer & Oncology Authors: Nikita Jhangiani Megha Philip Ismail Jatoi Source Type: research
MicroRNAs mediated interaction of tumor microenvironment cells with breast cancer cells during bone metastasis
Breast Cancer. 2023 Aug 14. doi: 10.1007/s12282-023-01491-0. Online ahead of print.ABSTRACTBreast cancer (BC) bone metastasis is primarily osteolytic and has limited therapeutic options. Metastasized BC cells prime the secondary environment in bone by forming a tumor niche, which favors their homing and colonization. The tumor microenvironment (TME) is primarily generated by the cancer cells. Bone TME is an intricate network of multiple cells, including altered bone, tumor, stromal, and immune cells. Recent findings highlight the significance of small non-coding microRNAs (miRNAs) in influencing TME during tumor metastasis...
Source: Breast Cancer - August 14, 2023 Category: Cancer & Oncology Authors: R L Akshaya I Saranya N Selvamurugan Source Type: research
Breast cancer screening guidelines: discrepancies raise concerns about validity
Breast Cancer. 2023 Aug 14. doi: 10.1007/s12282-023-01493-y. Online ahead of print.NO ABSTRACTPMID:37578598 | DOI:10.1007/s12282-023-01493-y (Source: Breast Cancer)
Source: Breast Cancer - August 14, 2023 Category: Cancer & Oncology Authors: Nikita Jhangiani Megha Philip Ismail Jatoi Source Type: research
Pathologic complete response and survival in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy
CONCLUSIONS: In eBC patients treated with NAC, taking into account HR expression subtype and other current clinicopathological features, HER2-low tumors did not appear to have different chemosensitivity or prognosis, compared to their HER2-0 counterparts.PMID:37561255 | DOI:10.1007/s12282-023-01490-1 (Source: Breast Cancer)
Source: Breast Cancer - August 10, 2023 Category: Cancer & Oncology Authors: Silvia Mihaela Ilie Nathalie Briot Guillaume Constantin Nicolas Roussot Alis Ilie Anthony Bergeron Laurent Arnould Fran çoise Beltjens Isabelle Desmoulin Didier Mayeur Cour èche Kaderbhai Audrey Hennequin Cl émentine Jankowski Marie Martine Padeano Hel Source Type: research
Pathologic complete response and survival in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy
CONCLUSIONS: In eBC patients treated with NAC, taking into account HR expression subtype and other current clinicopathological features, HER2-low tumors did not appear to have different chemosensitivity or prognosis, compared to their HER2-0 counterparts.PMID:37561255 | DOI:10.1007/s12282-023-01490-1 (Source: Breast Cancer)
Source: Breast Cancer - August 10, 2023 Category: Cancer & Oncology Authors: Silvia Mihaela Ilie Nathalie Briot Guillaume Constantin Nicolas Roussot Alis Ilie Anthony Bergeron Laurent Arnould Fran çoise Beltjens Isabelle Desmoulin Didier Mayeur Cour èche Kaderbhai Audrey Hennequin Cl émentine Jankowski Marie Martine Padeano Hel Source Type: research
Pathologic complete response and survival in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy
CONCLUSIONS: In eBC patients treated with NAC, taking into account HR expression subtype and other current clinicopathological features, HER2-low tumors did not appear to have different chemosensitivity or prognosis, compared to their HER2-0 counterparts.PMID:37561255 | DOI:10.1007/s12282-023-01490-1 (Source: Breast Cancer)
Source: Breast Cancer - August 10, 2023 Category: Cancer & Oncology Authors: Silvia Mihaela Ilie Nathalie Briot Guillaume Constantin Nicolas Roussot Alis Ilie Anthony Bergeron Laurent Arnould Fran çoise Beltjens Isabelle Desmoulin Didier Mayeur Cour èche Kaderbhai Audrey Hennequin Cl émentine Jankowski Marie Martine Padeano Hel Source Type: research
Pathologic complete response and survival in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy
CONCLUSIONS: In eBC patients treated with NAC, taking into account HR expression subtype and other current clinicopathological features, HER2-low tumors did not appear to have different chemosensitivity or prognosis, compared to their HER2-0 counterparts.PMID:37561255 | DOI:10.1007/s12282-023-01490-1 (Source: Breast Cancer)
Source: Breast Cancer - August 10, 2023 Category: Cancer & Oncology Authors: Silvia Mihaela Ilie Nathalie Briot Guillaume Constantin Nicolas Roussot Alis Ilie Anthony Bergeron Laurent Arnould Fran çoise Beltjens Isabelle Desmoulin Didier Mayeur Cour èche Kaderbhai Audrey Hennequin Cl émentine Jankowski Marie Martine Padeano Hel Source Type: research
Prognosis of post-neoadjuvant therapy patients who underwent immediate breast reconstruction: a SEER-based, propensity-matched study
CONCLUSION: In general, the application of IBR among post-NAT patients has steadily increased from 2010 to 2017. In the CR group, survival outcomes of post-NAT patients who received IBR were similar to those who received mastectomy alone. In the non-CR group, IBR was associated with potential survival benefits. More studies are expected to validate our findings.PMID:37505442 | DOI:10.1007/s12282-023-01489-8 (Source: Breast Cancer)
Source: Breast Cancer - July 28, 2023 Category: Cancer & Oncology Authors: Jiahao Pan Liying Peng Xiuwen Tong Xipei Chen Xinyun Xu Jian Zhang Source Type: research
Prognosis of post-neoadjuvant therapy patients who underwent immediate breast reconstruction: a SEER-based, propensity-matched study
CONCLUSION: In general, the application of IBR among post-NAT patients has steadily increased from 2010 to 2017. In the CR group, survival outcomes of post-NAT patients who received IBR were similar to those who received mastectomy alone. In the non-CR group, IBR was associated with potential survival benefits. More studies are expected to validate our findings.PMID:37505442 | DOI:10.1007/s12282-023-01489-8 (Source: Breast Cancer)
Source: Breast Cancer - July 28, 2023 Category: Cancer & Oncology Authors: Jiahao Pan Liying Peng Xiuwen Tong Xipei Chen Xinyun Xu Jian Zhang Source Type: research
Prognosis of post-neoadjuvant therapy patients who underwent immediate breast reconstruction: a SEER-based, propensity-matched study
CONCLUSION: In general, the application of IBR among post-NAT patients has steadily increased from 2010 to 2017. In the CR group, survival outcomes of post-NAT patients who received IBR were similar to those who received mastectomy alone. In the non-CR group, IBR was associated with potential survival benefits. More studies are expected to validate our findings.PMID:37505442 | DOI:10.1007/s12282-023-01489-8 (Source: Breast Cancer)
Source: Breast Cancer - July 28, 2023 Category: Cancer & Oncology Authors: Jiahao Pan Liying Peng Xiuwen Tong Xipei Chen Xinyun Xu Jian Zhang Source Type: research
